formulated a metal-organic supramolecular compound (nano PMI@CeO2) capable of restoring TP53 and sensitizing ferroptosis, markedly inhibiting tumor progression in a syngeneic transplant model of lung cancer, while maintaining excellent biocompatibility, thereby presenting a potential candidate drug for cancer treatment (122). This evidence concerns the gene TP53 and lung carcinoma.